目的检测切除修复交叉互补基因1(ERCC1)及表皮生长因子受体2(Cerb B-2)在中晚期胃癌组织中的表达,分析二者在不同组织学分级及有无淋巴结转移之间的差异性和相关性,探讨其临床意义。方法通过免疫组化方法检测30例中晚期胃癌组织中ERCC1及Cerb B-2的表达情况,各组间表达差异采用CMH或χ2检验,并采用Spearman分析二者的相关性。结果 Cerb B-2在高-中分化腺癌及低分化腺癌中表达阳性率分别为66.7%、55.6%,差异无统计学意义(P>0.05);ERCC1在高-中分化腺癌及低分化腺癌中表达阳性率分别为66.7%、83.3%,差异无统计学意义(P>0.05)。Cerb B-2在有无淋巴结转移中表达阳性率分别为66.7%、44.4%,差异无统计学意义(P>0.05);ERCC1在有无淋巴结转移中表达阳性率分别为76.2%、77.8%,差异无统计学意义(P>0.05)。二者在胃癌组织中表达无明显相关性(γ=0.007,P>0.05)。结论两者的检测可以列为化疗方案选择依据之一,顺铂与曲妥珠单抗二者可以联合作用于进展期胃癌患者。 Objective To detect the expression of ERCC1 and Cerb B-2 in advanced gastric cancer and to analyze the difference between them in different histological grade and lymph node metastasis Sex and relevance, to explore its clinical significance. Methods The expression of ERCC1 and Cerb B-2 in 30 cases of advanced gastric cancer was detected by immunohistochemistry. The differences of expression between groups were analyzed by CMH or χ2 test, and the correlation between them was analyzed by Spearman. Results The positive rates of Cerb B-2 in high-moderately differentiated adenocarcinoma and poorly differentiated adenocarcinoma were 66.7% and 55.6%, respectively, with no significant difference (P> 0.05). The positive rates of ERCC1 in high-moderately differentiated adenocarcinoma and low The positive rate of differentiated adenocarcinoma was 66.7% and 83.3%, respectively, with no significant difference (P> 0.05). The positive rates of Cerb B-2 in the presence or absence of lymph node metastasis were 66.7%, 44.4%, respectively, with no significant difference (P> 0.05). The positive rates of ERCC1 expression in lymph node metastasis were 76.2%, 77.8% The difference was not statistically significant (P> 0.05). There was no significant correlation between them in gastric cancer (γ = 0.007, P> 0.05). Conclusion The detection of both can be listed as one of the choice of chemotherapy regimens, and both cisplatin and trastuzumab can act in patients with advanced gastric cancer.